China SXT Pharmaceuticals (NASDAQ:SXTC) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of China SXT Pharmaceuticals (NASDAQ:SXTC) to a sell rating in a research report report published on Saturday morning.

Separately, Weiss Ratings raised China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

China SXT Pharmaceuticals Trading Up 12.9%

Shares of NASDAQ:SXTC opened at $4.10 on Friday. The business has a 50-day moving average of $110.02 and a two-hundred day moving average of $144.92. China SXT Pharmaceuticals has a fifty-two week low of $3.10 and a fifty-two week high of $83,758.80. The company has a quick ratio of 7.76, a current ratio of 7.94 and a debt-to-equity ratio of 0.02.

China SXT Pharmaceuticals (NASDAQ:SXTC) last issued its quarterly earnings data on Wednesday, July 1st. The company reported ($5.60) EPS for the quarter. The firm had revenue of $0.26 million during the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in China SXT Pharmaceuticals during the fourth quarter valued at about $36,000. Virtu Financial LLC grew its position in shares of China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after purchasing an additional 15,013 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of China SXT Pharmaceuticals in the third quarter worth about $78,000. Institutional investors and hedge funds own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.